Amaroq Therapeutics

2 known investors

Amaroq Therapeutics develops first-in-class therapies targeting long non-coding RNAs (lncRNAs) implicated in oncology and other diseases. The company uses proprietary platforms to discover, validate, and create precision medicines against disease-relevant lncRNAs, focusing initially on oncology programs with high unmet medical need.

Biotech